What is POMBILITI ATGA used for?

( ARTG ) POMBILITI (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency).

What pharmaceutical form is POMBILITI ATGA available in?

POMBILITI ATGA: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 105 mg/1 (INTRAVENOUS)

What are the side effects of POMBILITI ATGA?

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme

Can POMBILITI ATGA be used during pregnancy?

( AHT ) For the active ingredient cipaglucosidase alfa You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

What ATC class does POMBILITI ATGA belong to?

POMBILITI ATGA: ATC A16AB23. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

OTC

POMBILITI ATGA

105 mg/1, Injection, powder, lyophilized, for solution

INN: CIPAGLUCOSIDASE ALFA

Data updated: 2026-05-02

Available in:

🇨🇿🇩🇪🇬🇧🇵🇹

Form

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Dosage

105 mg/1

Route

INTRAVENOUS

Storage

—

About This Product

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.